Neurofeedback for COVID-19 Brain Fog: A Secondary Analysis.

Publication date: Feb 01, 2025

This secondary analysis technical report uses quantitative electroencephalography (qEEG) neurofeedback to treat brain fog, a group of cognitive challenges such as sluggish thinking, memory lapses, confusion, and poor focus, often observed in long COVID. In the original case report, a 34-year-old female patient was administered approximately 15 sessions of Z-score neurofeedback. Pretest and post-test neurofeedback training qEEG reported significant declines in high-beta activity, i. e., beta, Hi beta, beta 1, and beta 3, and notable increases in alpha and theta brainwaves. These improvements were most evident at electrode sites C4, F3, and P3. The patient reported improved attention and memory, reduced anxiety, and less pain, although depression reduction was less. These results suggest that a relatively short program of neurofeedback can assist in shifting the brain from hyperarousal to a calmer, more efficient state. This may potentially offer a non-pharmacological method for treating constant post-COVID brain fog. Additional studies are necessary to validate these findings.

Open Access PDF

Concepts Keywords
C4 brain fog
Covid covid-19
Neurofeedback mild-to-severe cognitive dysfunction
Old neurofeedback therapy
Pharmacological quantitative eeg (qeeg)
z-score neurofeedback

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Brain Fog
disease MESH confusion
disease MESH long COVID
disease MESH anxiety
disease MESH depression
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH cognitive dysfunction
disease IDO process
disease MESH memory loss
drug DRUGBANK Methionine
drug DRUGBANK Oxygen
drug DRUGBANK Palmidrol
disease MESH anosmia
disease MESH ageusia
disease MESH chest pain
disease IDO intervention
disease MESH infection
disease MESH obesity
disease MESH hypertension
disease MESH breathlessness
disease MESH smell disorder
disease MESH taste disorder
disease IDO blood
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO algorithm
disease IDO site
disease MESH attention deficit hyperactivity disorder
disease MESH insomnia
drug DRUGBANK Sodium lauryl sulfate
disease MESH clinical relevance
disease IDO temporal region
disease MESH neuroinflammation
disease MESH hypoxia
drug DRUGBANK Albendazole
disease MESH restlessness
disease IDO symptom
disease MESH syndrome

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *